Association Between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent metabolic disease. Muscle is known to influence NAFLD development. Therefore, this study aimed to determine the relationships among low muscle mass, NAFLD, and hepatic fibrosis using various definitions of low muscle mass and NAFLD diagnostic methods, including magnetic resonance imaging-based proton density fat fraction (MRI-PDFF).Methods: This cross-sectional study included 320 participants (107 males, 213 females) from the Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population cohort. Muscle mass was assessed using whole-body dual-energy X-ray absorptiometry and adjusted for the height squared, body weight, and body mass index (BMI). NAFLD was diagnosed using ultrasonography (US), MRI-PDFF, and the comprehensive NAFLD score (CNS). Hepatic fibrosis was assessed using magnetic resonance elastography. Multivariable logistic and linear regression analyses were performed to determine the aforementioned associations.Results: According to US, 183 participants (57.2%) had NAFLD. Muscle mass adjusted for body weight was associated with NAFLD diagnosed using US (odds ratio [OR], 3.00; 95% confidence interval [CI], 1.70 to 5.31), MRI-PDFF (OR, 2.00; 95% CI, 1.13 to 3.53), and CNS (OR, 3.39; 95% CI, 1.73 to 6.65) and hepatic fibrosis (males: β=-0.070, p<0.01; females: β=-0.037, p<0.04). Muscle mass adjusted for BMI was associated with NAFLD diagnosed by US (OR, 1.71; 95% CI, 1.02 to 2.86) and CNS (OR, 1.95; 95% CI, 1.04 to 3.65), whereas muscle mass adjusted for height was not associated with NAFLD.Conclusions: Low muscle mass was associated with NAFLD and liver fibrosis; therefore, maintaining sufficient muscle mass is important to prevent NAFLD. A prospective study and additional consideration of muscle quality are needed to strengthen the findings regarding this association.
Abstract
Objectives: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent metabolic disease. Muscle is known to influence NAFLD development. Therefore, this study aimed to determine the relationships among low muscle mass, NAFLD, and hepatic fibrosis using various definitions of low muscle mass and NAFLD diagnostic methods, including magnetic resonance imaging-based proton density fat fraction (MRI-PDFF).Methods: This cross-sectional study included 320 participants (107 males, 213 females) from the Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population cohort. Muscle mass was assessed using whole-body dual-energy X-ray absorptiometry and adjusted for the height squared, body weight, and body mass index (BMI). NAFLD was diagnosed using ultrasonography (US), MRI-PDFF, and the comprehensive NAFLD score (CNS). Hepatic fibrosis was assessed using magnetic resonance elastography. Multivariable logistic and linear regression analyses were performed to determine the aforementioned associations.Results: According to US, 183 participants (57.2%) had NAFLD. Muscle mass adjusted for body weight was associated with NAFLD diagnosed using US (odds ratio [OR], 3.00; 95% confidence interval [CI], 1.70 to 5.31), MRI-PDFF (OR, 2.00; 95% CI, 1.13 to 3.53), and CNS (OR, 3.39; 95% CI, 1.73 to 6.65) and hepatic fibrosis (males: β=-0.070, p<0.01; females: β=-0.037, p<0.04). Muscle mass adjusted for BMI was associated with NAFLD diagnosed by US (OR, 1.71; 95% CI, 1.02 to 2.86) and CNS (OR, 1.95; 95% CI, 1.04 to 3.65), whereas muscle mass adjusted for height was not associated with NAFLD.Conclusions: Low muscle mass was associated with NAFLD and liver fibrosis; therefore, maintaining sufficient muscle mass is important to prevent NAFLD. A prospective study and additional consideration of muscle quality are needed to strengthen the findings regarding this association.
참고문헌 (32)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55(6), pp.2005~2023 (2012)
- Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40(6), pp.1387~1395 (2004)
- Im HJ, "Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea", Clin Res Hepatol Gastroenterol, 45(4), pp.101526~ (2021)
- Delmonico MJ, "Longitudinal study of muscle strength, quality, and adipose tissue infiltration", Am J Clin Nutr, 90(6), pp.1579~1585 (2009)
- Shafiee G, "Prevalence of sarcopenia in the world : a systematic review and meta-analysis of general population studies", J Diabetes Metab Disord, 16, pp.21~ (2017)
- Chen LK, "Asian Working Group for Sarcopenia : 2019 consensus update on sarcopenia diagnosis and treatment", J Am Med Dir Assoc, 21(3), pp.300~307 (2020)
- Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48(1), pp.16~31 (2019)
- Pacifico L, "Nonalcoholic fatty liver disease is associated with low skeletal muscle mass in overweight", obese youths, 2020, pp.8, 158~
- Wang YM, "Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in Zhejiang Province, China: a cross-sectional observational study", BMC Geriatr, 21(1), pp.55~ (2021)
- Alferink LJ, "Nonalcoholic fatty liver disease in the Rotterdam study: about muscle mass, sarcopenia, fat mass, and fat distribution", J Bone Miner Res, 34(7), pp.1254~1263 (2019)
- Sinclair M, "Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions", Aliment Pharmacol Ther, 43(7), pp.765~777 (2016)
- 이승원, "Appendicular Skeletal Muscle Mass and Insulin Resistance in an Elderly Korean Population: The Korean Social Life, Health and Aging Project-Health Examination Cohort", Diabetes and Metabolism Journal, 39(1), pp.37~45 (2015), 대한당뇨병학회
- Kim G, "Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study", Hepatology, 68(5), pp.1755~1768 (2018)
- Hong KS, "Sarcopenia Is an independent risk factor for NAFLD in COPD : a nationwide survey(KNHANES 2008-2011)", Int J Chron Obstruct Pulmon Dis, 15, pp.1005~1014 (2020)
- Peng TC, "Nonalcoholic fatty liver disease and sarcopenia in a Western population(NHANES III) : the importance of sarcopenia definition", Clin Nutr, 38(1), pp.422~428 (2019)
- Kim Y, "Cohort profile: the Korean Genome and Epidemiology Study (KoGES) consortium", Int J Epidemiol, 46(2), pp.e20~ (2017)
- Koh SB, "Preliminary report : a serious link between adiponectin levels and metabolic syndrome in a Korean nondiabetic population", Metabolism, 59(3), pp.333~337 (2010)
- Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153(3), pp.753~761 (2017)
- Lee YH, "Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores", PLoS One, 9(9), pp.e107584~ (2014)
- Chen LK, "Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia", J Am Med Dir Assoc, 15(2), pp.95~101 (2014)
- Kim YS, "Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys", J Gerontol A Biol Sci Med Sci, 67(10), pp.1107~1113 (2012)
- Studenski SA, "The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates", J Gerontol A Biol Sci Med Sci, 69(5), pp.547~558 (2014)
- Altajar S, "Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease", J Clin Transl Hepatol, 8(4), pp.414~423 (2020)
- Kaser S, "Adiponectin and its receptors in non-alcoholic steatohepatitis", Gut, 54(1), pp.117~121 (2005)
- Aleffi S, "Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells", Hepatology, 42(6), pp.1339~1348 (2005)
- Pedersen BK, "Muscles, exercise and obesity: skeletal muscle as a secretory organ", Nat Rev Endocrinol, 8(8), pp.457~465 (2012)
- Batsis JA, "Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies", Nat Rev Endocrinol, 14(9), pp.513~537 (2018)
- Hamrick MW, "Fatty infiltration of skeletal muscle : mechanisms and comparisons with bone marrow adiposity", Front Endocrinol (Lausanne), 7, pp.69~ (2016)
- Lim S, "Sarcopenic obesity : prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging(KLoSHA)", Diabetes Care, 33(7), pp.1652~1654 (2010)
- Caussy C, "Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials", Hepatology, 68(2), pp.763~772 (2018)
- Yodoshi T, "Muscle mass is linked to liver disease severity in pediatric nonalcoholic fatty liver disease", J Pediatr, 223, pp.93~99 (2020)
- Linge J, "Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD", JHEP Rep, 3(1), pp.100197~ (2020)